Member Info for B2HS2L

Recently had a look for suppliers of interferon Beta.
I was surprised there were not more suppliers.
Apologies if this has been asked before:
Does anyone know if this is a difficult drug to manufacture please.
Thanks in advance.

My apologies, - RNS 15.04.2010 should read RNS 15.04.2020:

Hi chester,

Agree with your 11:17 post, and also "I would really appreciate someone with an accountancy background having a dig into the last few years RNS's / Hardman Reports and giving it a more professional eye," - not forgetting the 2018 Annual report.

How long do you think is long enough to arrange a new loan, seeing as we haven't succeeded since Midcap
renegotiation in November last year?

This is why the new leased processing facility is not being made fit for our purposes, and our working capital has dwindled.

"Don't you get the feeling that the management have done everything they could possibly do to extend the cash runway"

Yes, good, but the reason to extend the cash runway is to do a deal facilitating progress.
It doesn't seem likely a placing is being considered, but you never know.
We must be looking for a unique form of funding to justify this length of negotiating time.

RNS 15.04.2010: "The Board continues to be encouraged by discussions with potential investors".

I'm starting to think however that because loan discussions have become protracted, that more than a
simple loan is being considered.
'Investors' may have deals to offer or joint ventures for the board to consider, not just a loan.

If there are many 'investor' offers, this would take considerably longer than just the terms of competing loans.

Changing the Exec. Chairman may mean going over ground already covered, due to Jonathan reconsidering the options,
(and reconsidering them in the light of dirt cheap / free Govnt loans).

Will sign off here, but it may be worth further considering the above before dismissing the above as 'all conjecture'.

Looking forward to reading about 'the bigger picture' in the 2019 Annual report due in June.

Appologies if this has been posted before.

https://www.cnbc.com/2020/04/22/coronavirus-saliva-tests-could-be-as-accurate-or-better-than-nasal-swabs-yale-researchers-say.html

Coronavirus saliva tests could be as accurate as or better than nasal swabs, Yale researchers say

“Taken together, our findings demonstrate that saliva is a viable and more sensitive alternative to nasopharyngeal swabs and could enable at-home self-administered sample collection for accurate large-scale SARS-CoV-2 testing.”

The study was published the day after the first at-home coronavirus test kit was approved by the U.S. Food and Drug Administration.

The reason our share price is so low is because we have lost some large Institutional Investors.

If we were to be able to put the clock back our sp would be a couple of pence higher, perhaps more.

So if we find some large II's to invest a similar amount as before, we would not be discussing consolidation.

I can imagine that happening should finances be resolved, and we could start this company building it's destiny.

Management keep finding ways to kick that can down the road though.

Aren't you sick of hearing 'we are still in loan discussions' with no action?

https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---20-april-2020

Near end of 20.04.2020 article:

"After 54 days without a case, there have now been six cases of Ebola in the past 10 days. We are continuing to work hard with our partners to support the government to ensure that this spark does not become a larger fire."

How about selling advertising space on the lateral flow device to the brewer of Corona beer?
It seems to be sold across the globe.
It would be great if the proceeds paid for every nations health care workers to have a well deserved holiday,
as this is the device that will allow them the time.

Chaps,

We cant go to market with a "LIFE SAVIN - LOCKDOWN LIFTIN - WORLD BEATIN" product called SNG001 surely?

Best idea for naming this product wins a lolipop, and features in the next video with Richard after lockdown ends!

...OK, - what else were you going to do tomorrow??

FWIW, my mode of operation is to top up a little at a time, because the sp is so low.
A small amount of cash buys a lot of shares.

Hi chester,
We have both sought to identify break even recently.

In the 06.02.2020 Hardman report, under Profit and Loss:

"EBITDA: Management remains focused on the continuing trend towards EBITDA breakeven by the end of fiscal 2021."

I have a lot more digging to do, but thought you would be interested in this finding :)

The two most important positive features of this product, is that at no point in it's use, or waiting for a result, does it require a power supply or require a doctor or lab technician to provide a result. - Use it anywhere.

Once you have a negative result, it won't be long before it is prudent to use another if living/working in a high risk environment.

When US market opens pm, I am expecting sp +5 to 10%, (I'm rather conservative), but I suppose it depends on how much coverage the story gets first thing.

Congrats to AVCT for developing the Affimer test faster than they initially thought.
This was derisked by having done a similar job for Zika virus.
AFAIK, the Zika test never went to approval or production.
So for me this is the riskiest bit - making the Affimer CV test work on the lateral flow device.
There is risk in any project development, and we know that Cytiva has helped with information and
assistance with doing this, and the combined teams are working round the clock to achieve success.

The pressure the NHS is under is not sustainable, and we all need this to succeed,
so when we applaud the NHS for their stirling work, spare a thought for Avacta staff
and their colleagues in Cytiva.
Bravo Alistair.

Bluemoon73, If you are correct, then it will guarantee that USA will get a second spike
of viral infection in the population.
This will probably occur before presidential elections, and you can't have rallies with a
concurrent lockdown and/ or 2meter safety space.
Any more deaths after the population thought Corona Virus was a thing of the past, is possibly
going to swing the result away from Trump.
It's possible he might try to postpone the election in the event of another lockdown disallowing due electoral process.
Don't the individual states have the right to remove lockdowns now?

I have grown disillusioned with the old story that TRX still seek a loan.
I agree that present circumstances will make a loan agreement more difficult, but not impossible.
I think the TRX board dislike the present MidCap loan, and also believe they are in a race to break even now US loans have allowed an extension of the financial runway:

It is worth considering the following wrt attitude to MidCap loan:

Date of original loan agreement 04.06.2019.
Exec Chair John Samuel
CEO Steve Couldwell
CFO Gareth Jones

Currently Gareth Jones is CEO and performing the task of CFO.
Interim non-executive Chair is now Jonathan Glenn.

So two of those who liked the deal in June last year are gone.
Gareth Jones and Jonathan Glenn may want something new, particularly if the company reaches break even.

Also:

If a loan were to be negotiated now, if TRX had achieved break even, and with the financial situation improving,
the terms of the negotiated loan would be better than the present MidCap loan terms.
1 The German Tissue Bank is now self-sufficient (Jan 2020), and by now could be profitable
assuming no furloughs recently.
2 The second shift is set to achieve full productivity at the end of H1 2020 as per 22.01.2020 RNS, and if so we cannot be far from break even, as "implementation of the previous cost saving initiatives is ongoing" - (RNS 15.04.2020).

I still think that TRX has not requested a drawdown of tranche 2 of the present loan.

I think the board's No 1 priority is to get to break even before the first MidCap loan repayment (01.07.2020),
and thus qualify for better loan terms.

Annual Results for the year ended 31 December 2018 were published on 04.06.2019, so I expect a June 2020 date for year ended 31 December 2019, where more detail could become visible.

For Info:
Tissue Regenix Group - Unaudited Interim Results Tue, 10th Sep 2019:
GBM-v revenue growth of 19% to £1.1m (H1 2018: £0.9m)
"Our controlled joint venture GBM-V is now largely self-sustainable and during the period increased revenue by 19% though the sale of corneal implants, whilst it also manages the regulatory process for the CardioPure products in Germany, which remains on track for a launch during 2020." (Unclear what the launch costs might be).

Trading Update Wed, 22nd Jan 2020:
Our joint venture, GBM-V saw continued growth of its corneal business and has become financially self-sufficient.
GBM-v Division: 2019 £2.1Mil. Actual 2018 £1.8Mil
Percentage change (GBP) 16%, Percentage change (constant currency) 13%.

Appologies if this has been posted before.

https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---20-april-2020

..."We want to re-emphasize that easing restrictions is not the end of the epidemic in any country.

Ending the epidemic will require a sustained effort on the part of individuals, communities and governments to continue suppressing and controlling this deadly virus.

So-called lockdowns can help to take the heat out of a country’s epidemic, but they cannot end it alone.

Countries must now ensure they can detect, test, isolate and care for every case, and trace every contact.

We welcome the accelerated development and validation of tests to detect COVID-19 antibodies, which are helping us to understand the extent of infection in the population.

WHO is providing technical, scientific and financial support for the rollout of sero-epidemiologic surveys across the world.

Early data from some of these studies suggest that a relatively small percentage of the population may have been infected, even in heavily affected areas – not more than 2 to 3 percent.

While antibody tests are important for knowing who has been infected, tests that find the virus are a core tool for active case finding, diagnosis, isolation and treatment.

One of WHO’s priorities is to work with partners to increase the production and equitable distribution of diagnostics to the countries that need them most.

To achieve that, WHO has worked with FIND, the Foundation for Innovative New Diagnostics, and the Clinton Health Access Initiative, to identify and validate five tests that can be manufactured in large quantities.

Working together with the Global Fund, UNICEF and Unitaid, we have now placed orders for 30 million tests over the next four months.

The first shipments of these tests will begin next week, through the United Nations Supply Chain we have established with the World Food Programme and other partners."....

Also

"After 54 days without a case, there have now been six cases of Ebola in the past 10 days. We are continuing to work hard with our partners to support the government to ensure that this spark does not become a larger fire."

Google
avacta-group-ceo-alastair-smith-rapid-covid19-test-strips-available-summer-interview/412811668

and you will get the link discussed below!!

Add
https://www.*************interviews
to
.com/avacta-group-ceo-alastair-smith-rapid-covid19-test-strips-available-summer-interview/412811668

to get the whole link.
Thanks Mr spacetomatoe for the original link to a different Alistair Smith interview.

Here is another short interview on the subject of the Affimer test integration with Cytiva lateral flow device.
https://www.***************************/avacta-group-ceo-alastair-smith-rapid-covid19-test-strips-available-summer-interview/412811668

Alistair discusses timescales to get Affimer test integrated with lateral flow devise, and Cytiva to distribute.

CE mark is the only approval discussed, so I make the guarded assumption that EU / Middle East where CE label is required / highly regarded as being the first launch areas.

I've set my posts per page to 100.

Redial has posted @ 9.11, 9.17, 9.23, 9.26, 9.28, 10.30, 10.32, 11.05, 11.37.

His name appears in replies posted 20 times, (so 20% of the 100 replies are to Redial).

If he's being paid his boss will not be unhappy.

A filter is a filter and there for a reason guys, it should not be all about redial.